Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.19 USD | -2.63% | -4.24% | +38.03% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.03% | 293M | |
+4.16% | 70.78B | |
+10.72% | 9.15B | |
-17.03% | 4.84B | |
+37.51% | 4.22B | |
+3.92% | 3.92B | |
+18.14% | 2.55B | |
-24.13% | 2.26B | |
-29.70% | 2.24B | |
+9.09% | 1.92B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- CorMedix : Needham & Co Adjusts CorMedix PT to $29 From $31, Maintains Buy Rating